Author:
Paul Friedemann,Seifert Roland
Publisher
Springer Berlin Heidelberg
Reference105 articles.
1. Albanese A, Sormani MP, Gattorno G, Schiavetti I (2022) Covid-19 severity among patients with multiple sclerosis treated with cladribine: a systematic review and meta-analysis. Mult Scler Relat Disord 68:104156
2. Albrecht P, Bjorna IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdic J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T (2018) Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Ther Adv Neurol Disord 11:1756286418803248
3. Arznei-Telegramm (2020) Pridinol (Myofortin, Myditin): Werbung Ja – Daten Nein. Arznei Telegr 51:6–7
4. Arzneimittelkommission der deutschen Ärzteschaft (2009) Progressive multifokale Leukenzephalopathie (PML) unter Behandlung einer multiplen Sklerose mit Natalizumab (Tysabri). Dtsch Arztebl 106:A2208
5. Behm K, Morgan P (2018) The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review. Disabil Rehabil 40:1733–1744